Liquidia files litigation challenging regulatory exclusivity for rival's inhaled drug
Aug 22 (Reuters) - Liquidia Corp LQDA.O said on Thursday that it has filed litigation in the U.S. District Court of the District of Columbia that challenges the recent decision by the U.S. Food and Drug Administration to grant three-year exclusivity to United Therapeutics' UTHR.O inhaled drug for a type of lung disorder. (Reporting by Sneha S K; Editing by Mrigank Dhaniwala) ((Sneha.SK@thomsonreuters.com;))
Recent news on Liquidia
See all newsUS STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing